Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.

Fayez Hanna, Ajay Prakash, Ebony Allan, Alhossain A Khalafallah

Abstract readCase Reports

In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

2.0field-weighted citation impact, top 13% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Fayez HannaFaculty of Health Sciences, University of Tasmania, Launceston, Tasmania, Australia.

Ajay PrakashHaematology, Tasmanian Medical Laboratory, Launceston, Tasmania, Australia.

Ebony AllanHaematology Department, Specialist Care Australia, Launceston, Tasmania, Australia.

Alhossain A KhalafallahFaculty of Health Sciences, University of Tasmania, Launceston, Tasmania, Australia.ORCID http://orcid.org/0000-0002-2399-3311

University of Tasmania · AULaunceston General Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 70-year-old man presented with left loin pain without urinary symptoms. Initial investigations with CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass and enlarged prostate. A prostatic-specific antigen (PSA) was alarmingly high at 4750 μg/L (normal <4.0 μg/L). Further investigations included positron emission tomography (PET); both prostate-specific membrane antigen and 18-fluorodeoxyglucose as well as bone scan and bone marrow examination confirmed dual malignancies with B-cell non-Hodgkin's lymphoma (B-NHL) and wide spread metastatic prostatic adenocarcinoma (PA) to the skull, spine, pelvis, liver and lungs. The patient was treated with six cycles of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin(R-EPOCH) containing regimen for B-NHL and goserelin hormonal therapy for PA. Restaging with PET scans thereafter showed complete remission of NHL with disappearance of his metastatic PA and normalisation of PSA levels. R-EPOCH regimen and antiandrogen therapy resulted in a good outcome and remission of both malignancies.

Indexed as

AdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCyclophosphamideDoxorubicinEtoposideHumansLymphoma, Large B-Cell, DiffuseMaleNeoplasms, Multiple PrimaryPositron-Emission TomographyPrednisoneProstate-Specific AntigenProstatic NeoplasmsRituximabCyclophosphamideDoxorubicinEtoposidePrednisoneProstate-Specific AntigenRituximabVincristinemalignant and benign haematologymalignant disease and immunosuppressionprostate cancer

Identifiers

PMID29549134

DOI10.1136/bcr-2017-223637

PMCPMC5878372

OpenAlexW2793560392

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.